SUPPLEMENTARY METHODS

MHC screening and study groups
A critical issue that we considered in the study design was the assignment of the 12 animals to the two study groups (i.e., IL-7 treatment and control) in order to avoid potential biases in SIVdisease susceptibility. Since previous work identified MHC class-I alleles with disease/viral load-protective (Mamu-A01, Mamu-A08, Mamu-B08) or -enhancing (Mamu-B01) properties [1] [2] [3] [4] , we pre-screened the animals for defined Mamu haplotypes. A positive score (+1) was attributed to the presence of Mamu-A01, A08 or B08; a negative score (-1) to the presence of Mamu-B01 (Table S2 ). The final study groups were balanced considering both MHC scores and baseline counts of peripheral blood CD3 + and CD4 + T lymphocytes (Table S2) .
Statistical analysis using the O'Brien test
To compare untreated and IL-7-treated animals with respect to changes from baseline to multiple time points simultaneously we used the O'Brien test, which is a natural extension of the Wilcoxon rank sum test to accommodate multiple time points per subject. The analysis was used to compare simultaneously the changes from baseline to each time point during the treatment period (day 7, 14, 21, 28, and 35) . First, we ranked changes from baseline to each of the time points separately, and then for each animal we averaged the ranks across the time points. To assess statistical significance, a permutation test was used. Under the null hypothesis of no effect of IL-7 treatment, one should not be able to distinguish treated monkeys from controls; the control monkeys could have been any group of 5 selected from the 11 total (excluding monkey #744 for which several time points were missing). Considering that there are 462 ways to select 5 subjects from 11, for each of these relabelings, we computed the difference between the average for animals labeled as "IL-7-treated" and the average for animals labeled as "untreated".
Afterwards, we computed the proportion of relabeled datasets that produced a mean difference at least as extreme as the actual trial data. rather than in CD4 + T cells [5] . In agreement with these previous observations, our rapid progressors (RP) showed persistently higher levels of SIV plasma viremia ( Figure S1A ) and antigenemia ( Figure S1B ), compared to conventional progressors (CP), as well as overall higher numbers of circulating CD4 + T cells, even though the difference reached statistical significance only on day 62 post-infection ( Figure S1C ). Although it is impossible, without extending the study to a larger group of animals, to establish if the RP course was affected by IL-7 treatment, the fact that two animals in each group progressed rapidly suggests that IL-7 did not influence this unique form of SIV-disease evolution.
Since the rapid disease course has been associated with an unusual pathogenesis [5], which is likely influenced by genetic factors and insensitive to IL-7 treatment, we reasoned that the inclusion of RP animals could be a confounding factor in our study, and therefore we reanalyzed all the immunological and virological data after exclusion of these 4 animals. This reanalysis showed no major changes in the statistical comparisons between treated and untreated animals regarding SIV viremia and antigenemia ( Figure S2A ), CD4 + , CD8 + , naïve, memory and effector T cells in peripheral blood ( Figure S2B ), ileum and lymph nodes (data not shown).
However, the exclusion of RP animals had important effects on the analysis of T-cell apoptosis in lymph nodes, as described in the main text.
Changes in T-cell subpopulations in acutely SIV-infected macaques
The O'Brien permutation test was used to simultaneously compare the changes in naïve, memory and effector CD3 + , CD4 + and CD8 + T cells from baseline to all the time points during the treatment period (day 7-35 post-infection) in IL-7-treated versus untreated animals. As shown in Figure S3A , this analysis demonstrated that the changes in the total numbers of CD3 + , CD4 + and CD8 + T cells were significantly different in IL-7-treated and untreated macaques ( Figure S3A ).
Likewise, significant differences between IL-7-treated and untreated animals were also observed for naïve, memory and effector CD4 + and CD8 + T cells, as well as for naïve and effector CD3 + T cells, but not for memory CD3 + T cells ( Figure S3B ). However, when the analysis of changes was restricted to day 14 post-infection, the differences between IL-7-treated and untreated animals were significant for all T-cell subpopulations (not shown). * The MHC score was calculated by attributing a positive score (+1) to alleles associated with protection from SIV disease/viral load and a negative score (-1) to alleles associated with increased viral load/accelerated disease progression; no score was attributed to alleles with no known effects on SIV disease progression. ** n.d. = none detected. The animals were negative for the MHC alleles tested (A01, A02, A08, A11, B01, B03, B04, B08, B17). Figure S1 . Levels of SIV replication and CD4 + T cells in conventional progressor (CP) versus rapid progressor (RP) SIV-infected macaques. Mean levels (± SEM) of SIV plasma viremia (A) and p27 Gag antigenemia (B) in CP (orange) and RP (green). RP animals showed higher levels of both SIV viremia and antigenemia compared to CP at several time points, starting on day 18 post-infection, as indicated by the asterisks (*p < 0.05, ** p < 0.01, by Wilcoxon rank sum test). (C) Mean absolute numbers (± SEM) of circulating CD4 + T cells in CP (orange) and RP (green). A significant difference was observed on day 62 post-infection, when RP had higher mean levels of circulating CD4 + T cells compared to CP, as indicated by the asterisk (p < 0.042, by Wilcoxon rank sum test). 
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